|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's range||208.00 - 208.20|
|52-week range||187.25 - 239.41|
|Beta (5Y monthly)||0.11|
|PE ratio (TTM)||39.96|
|Forward dividend & yield||2.17 (1.04%)|
|Ex-dividend date||02 Sep 2021|
|1y target est||N/A|
After discussing a potential deal since March, the companies were now in advanced talks and CSL, the world's largest maker of blood plasma treatments, was carrying out due diligence on the Swiss firm, according to reports in The Australian Financial Review and The Australian. Both Vifor Pharma and CSL said in separate statements that they will not comment on the speculation. Morgan Stanley analysts said in a research note that CSL may be seeking diversification because blood plasma collections - where it pays people to give blood, which it then converts to treatments - remained depressed due to COVID-19 restrictions.
Seqirus, a global leader in influenza prevention and a business of CSL Limited (ASX:CSL), today announced that The New England Journal of Medicine has published absolute efficacy data on the company's cell-based quadrivalent influenza vaccine (QIVc) from a randomized controlled trial (RCT) which met its primary endpoint.1 The study indicates that the seasonal influenza vaccine was effective and produced a sufficient immune response against influenza in children and adolescents ≥2 to <18 years of
Health Canada's Approval of FOCLIVIA® (An Adjuvanted, Egg-Based A Strain H5N1 Pandemic Influenza Vaccine) Meets Key Requirement as Pandemic PartnerMONTREAL, March 23, 2021 /PRNewswire/ -- Seqirus, a world leader in influenza vaccines and pandemic response, announced today that following Health Canada's approval of FOCLIVIA® (adjuvanted, egg-based A strain H5N1 pandemic influenza vaccine), the Company is ready to fulfil its role in Canada's influenza pandemic preparedness plans.Seqirus Canada is an influenza pandemic vaccine partner to the Canadian Government through the Public Health Agency of Canada (PHAC).